ENTRY       D09729                      Drug
NAME        Lixisenatide (JAN/USAN/INN);
            Adlyxin (TN);
            Lyxumia (TN)
PRODUCT     ADLYXIN (sanofi-aventis U.S. LLC)
FORMULA     C215H347N61O65S
EXACT_MASS  4855.5443
MOL_WEIGHT  4858.4904
SEQUENCE    His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu
            Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser
            Ser Gly Ala Pro Pro Ser Lys Lys Lys Lys Lys Lys
  TYPE      Peptide
CLASS       Antidiabetic agent
             DG02044  Hypoglycemic agent
              DG01493  GLP-1 receptor agonist
REMARK      Therapeutic category: 2499
            ATC code: A10BJ03
            Product: D09729<JP/US>
            Product (mixture): D11034<JP/US>
EFFICACY    Antidiabetic, Glucagon-like peptide 1 (GLP-1) receptor agonist
  DISEASE   Type 2 diabetes mellitus [DS:H00409]
TARGET      GLP1R [HSA:2740] [KO:K04581]
  PATHWAY   hsa04080(2740)  Neuroactive ligand-receptor interaction
            hsa04911(2740)  Insulin secretion
INTERACTION  
STR_MAP     map07051  Antidiabetics
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             A ALIMENTARY TRACT AND METABOLISM
              A10 DRUGS USED IN DIABETES
               A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
                A10BJ Glucagon-like peptide-1 (GLP-1) analogues
                 A10BJ03 Lixisenatide
                  D09729  Lixisenatide (JAN/USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Blood Glucose Regulators
              Antidiabetic Agents
               GLP-1 Receptor Agonist
                Lixisenatide
                 D09729  Lixisenatide (JAN/USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              24  Hormones
               249  Miscellaneous
                2499  Others
                 D09729  Lixisenatide (JAN/USAN/INN)
            Drug groups [BR:br08330]
             Antidiabetic agent
              DG02044  Hypoglycemic agent
               DG01493  GLP-1 receptor agonist
                D09729  Lixisenatide
            Drug classes [BR:br08332]
             Antidiabetic agent
              DG01493  GLP-1 receptor agonist
               D09729  Lixisenatide
              DG02044  Hypoglycemic agent
               D09729  Lixisenatide
            Target-based classification of drugs [BR:br08310]
             G Protein-coupled receptors
              Secretin receptor family
               Glucagon
                GLP1R
                 D09729  Lixisenatide (JAN/USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D09729
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D09729
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D09729
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09729
DBLINKS     CAS: 320367-13-3
            PubChem: 124490469
            ChEBI: 85662
///
